SE9700934D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE9700934D0
SE9700934D0 SE9700934A SE9700934A SE9700934D0 SE 9700934 D0 SE9700934 D0 SE 9700934D0 SE 9700934 A SE9700934 A SE 9700934A SE 9700934 A SE9700934 A SE 9700934A SE 9700934 D0 SE9700934 D0 SE 9700934D0
Authority
SE
Sweden
Prior art keywords
new formulation
formulation
hydroxy
density
treatment
Prior art date
Application number
SE9700934A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Friess
Harald Heckenmueller
Oliver Szambien
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20406161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9700934(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9700934A priority Critical patent/SE9700934D0/xx
Publication of SE9700934D0 publication Critical patent/SE9700934D0/xx
Priority to GR980100096A priority patent/GR980100096A/el
Priority to NL1008575A priority patent/NL1008575C2/nl
Priority to FR9803077A priority patent/FR2760638A1/fr
Priority to BR9808140-3A priority patent/BR9808140A/pt
Priority to BE9800201A priority patent/BE1011837A5/fr
Priority to EP98909944A priority patent/EP1003524A1/en
Priority to PCT/SE1998/000455 priority patent/WO1998041212A1/en
Priority to HU00008500000850A priority patent/HUP0000850A3/hu
Priority to JP54042198A priority patent/JP2001519782A/ja
Priority to AU64301/98A priority patent/AU6430198A/en
Priority to PL98335700A priority patent/PL335700A1/xx
Priority to CA002283297A priority patent/CA2283297A1/en
Priority to US09/068,823 priority patent/US6197341B1/en
Priority to NO994431A priority patent/NO994431L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE9700934A 1997-03-14 1997-03-14 New formulation SE9700934D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE9700934A SE9700934D0 (sv) 1997-03-14 1997-03-14 New formulation
GR980100096A GR980100096A (el) 1997-03-14 1998-03-06 Νεα συνθεση βαλσαλαζιδης
NL1008575A NL1008575C2 (nl) 1997-03-14 1998-03-12 Nieuwe formulering.
FR9803077A FR2760638A1 (fr) 1997-03-14 1998-03-12 Formulation de balsalazide
CA002283297A CA2283297A1 (en) 1997-03-14 1998-03-13 New formulation
PL98335700A PL335700A1 (en) 1997-03-14 1998-03-13 Novel preparation
BE9800201A BE1011837A5 (fr) 1997-03-14 1998-03-13 Nouvelle composition de balsalazide.
BR9808140-3A BR9808140A (pt) 1997-03-14 1998-03-13 Formulação unitária
EP98909944A EP1003524A1 (en) 1997-03-14 1998-03-13 New formulation
PCT/SE1998/000455 WO1998041212A1 (en) 1997-03-14 1998-03-13 New formulation
HU00008500000850A HUP0000850A3 (en) 1997-03-14 1998-03-13 New formulation contg. derivatives of balsalazide new formulation contg. derivatives of balsalazide
JP54042198A JP2001519782A (ja) 1997-03-14 1998-03-13 新規製剤
AU64301/98A AU6430198A (en) 1997-03-14 1998-03-13 New formulation
US09/068,823 US6197341B1 (en) 1997-03-14 1998-05-14 Formulations of balsalazide and its derivatives
NO994431A NO994431L (no) 1997-03-14 1999-09-13 Ny formulering

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700934A SE9700934D0 (sv) 1997-03-14 1997-03-14 New formulation

Publications (1)

Publication Number Publication Date
SE9700934D0 true SE9700934D0 (sv) 1997-03-14

Family

ID=20406161

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9700934A SE9700934D0 (sv) 1997-03-14 1997-03-14 New formulation

Country Status (15)

Country Link
US (1) US6197341B1 (xx)
EP (1) EP1003524A1 (xx)
JP (1) JP2001519782A (xx)
AU (1) AU6430198A (xx)
BE (1) BE1011837A5 (xx)
BR (1) BR9808140A (xx)
CA (1) CA2283297A1 (xx)
FR (1) FR2760638A1 (xx)
GR (1) GR980100096A (xx)
HU (1) HUP0000850A3 (xx)
NL (1) NL1008575C2 (xx)
NO (1) NO994431L (xx)
PL (1) PL335700A1 (xx)
SE (1) SE9700934D0 (xx)
WO (1) WO1998041212A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
ATE460394T1 (de) * 2000-08-29 2010-03-15 Biocon Ltd 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
CA2495537C (en) 2000-08-29 2010-03-30 Nobex Corporation Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
WO2005074908A1 (en) 2004-02-06 2005-08-18 Borody, Thomas, Julius Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
ATE472999T1 (de) * 2004-05-28 2010-07-15 Salix Pharmaceuticals Inc Prävention, behandlung und linderung strahlungsinduzierter enteritis
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2816276A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
AU2007257174B2 (en) * 2006-06-06 2012-07-12 Gicare Pharma Inc. Salts of trimebutine and N-desmethyl trimebutine
AU2011245455A1 (en) 2010-04-26 2012-11-15 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045429A (en) 1970-03-06 1977-08-30 Pharmacia Aktiebolag 4-(4-Hydroxy- or acetoxy-3-carbomethoxyphenylazo)-benzenesulphonyl chloride
BE791889A (fr) 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
JPS57500432A (xx) * 1980-03-20 1982-03-11
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
GB2080796B (en) * 1980-07-21 1983-10-12 Biorex Laboratories Ltd 2-hydroxy-5-phenylazobenzoic acid derivatives
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation

Also Published As

Publication number Publication date
NO994431D0 (no) 1999-09-13
CA2283297A1 (en) 1998-09-24
FR2760638A1 (fr) 1998-09-18
WO1998041212A1 (en) 1998-09-24
AU6430198A (en) 1998-10-12
PL335700A1 (en) 2000-05-08
NO994431L (no) 1999-09-13
JP2001519782A (ja) 2001-10-23
GR980100096A (el) 1998-11-30
NL1008575C2 (nl) 1999-09-10
EP1003524A1 (en) 2000-05-31
HUP0000850A3 (en) 2000-10-30
NL1008575A1 (nl) 1998-09-15
US6197341B1 (en) 2001-03-06
BE1011837A5 (fr) 2000-02-01
BR9808140A (pt) 2000-03-28
HUP0000850A2 (hu) 2000-09-28

Similar Documents

Publication Publication Date Title
SE9700934D0 (sv) New formulation
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
ES2192839T3 (es) Timosina beta 4 oxidada.
NO20000688D0 (no) Anvendelse av lokalt avleverte metallioner for behandling av periodontal sykdom
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
BR9809185A (pt) Diidropiranos fundidos
DE69429202D1 (de) Therapeutischer Wirkstoff für Erkrankungen des Verdauungstraktes
TR200101120T2 (tr) Serin proteaz inhibitörü
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
PT998287E (pt) Utilizacao de levobupivacaina
DK465488A (da) Farmaceutisk praeparat indeholdende en triazol-forbindelse
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
EE9900450A (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
TR199800841A2 (xx) �kame edilmi� 6- ve 7-aminotetrahidroisokinolinkarbon asitleri.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
GB9420747D0 (en) 1,5 benzodiazepine derivatives
DE69636790D1 (de) Interferon-beta gegen knochenerkrankungen
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
TR199700921T1 (xx) �nsanlarda g�r�len herpes-vir�s-8&#39;in tedavisinde pensiklovir&#39;in kullan�lmas�.
ITRM970235A0 (it) Catetere per la diagnosi e il trattamento dell&#39;eiaculazione precoce
DK1007047T3 (da) Anvendelse af mizolastin til fremstilling af et lægemiddel beregnet til inflammationsbehandling